VivoSeq
Oncology

Urothelial Carcinoma

170

Pipeline Programs↗

69

Active Trials↗

74

Companies Involved↗

Urothelial Carcinoma is a highly competitive landscape with 170 programs across 74 companies. The most active players are Shandong TheraWisdom Biopharma Co., Ltd., ALX Oncology Inc., Ikena Oncology. 6 therapies are approved with 20 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

80/100

Pipeline Velocity

37/100

Mech. Concentration

6/100

Completion Rate

55/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shandong TheraWisdom Biopharma Co., Ltd.

1 program

Phase 1A

ALX Oncology Inc.

1 program

Phase 1I

Ikena Oncology

1 program

Phase 1F

Flare Therapeutics Inc.

1 program

Phase 1P

Principia Biopharma, a Sanofi Company

1 program

Phase 1B

Beijing Biotech

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical8

Avelumab

EMD Serono

Toripalimab

Coherus Oncology, Inc.

Adjuvant Chemotherapy

Nizhny Novgorod Regional Clinical Oncology Center

BGJ398

Novartis

EP0057

Ellipses Pharma

Phase 121

Nab-Paclitaxel

Bristol-Myers Squibb

Cyclophosphamide

Baxter Healthcare Corporation

Niraparib

Glaxo Dba Glaxosmithkline

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Fludarabine

Sanofi

Phase 2115

Pemetrexed Disodium

Gynecologic Oncology Group

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Tipifarnib

Kura Oncology, Inc.

Durvalumab

AstraZeneca

Retifanlimab

Incyte

Phase 320

Disitamab Vedotin

Pfizer

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Paclitaxel

Teva

Infigratinib

Helsinn Healthcare SA

Atezolizumab

Roche

Approved6

Talazoparib

Pfizer

Erdafitinib

Johnson & Johnson

Mitomycin

UroGen Pharma Ltd.

Bicalutamide

Istituto Clinico Humanitas

Palbociclib

Pfizer

Analysis

Modality Breakdown

78%

Small molecule

143 of 183 classified programs — the dominant modality here.

22%ALL OTHERSMonoclonal antibody2916%Antibody–drug conjugate63%Protein / enzyme53%

Small molecule leads; the ring shows all 183 classified programs, each share of the total. Modality classified for 100% of 201 pipeline programs.

Analysis

Trial Status

194

clinical trials

Completed51 · 26%
Recruiting36 · 19%
Terminated35 · 18%
Unknown status30 · 15%
Active, not recruiting23 · 12%
Not yet recruiting10 · 5%
Other9 · 5%

Clinical Trials

Trial Activity

194 trials

Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
Recruiting·—·Phase 2·NCT04617756·50 enrolled
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
Recruiting·YYung NA·Phase 2·NCT06257017·20 enrolled
Bio Clinical Collection of Urothelial Carcinoma
Recruiting·UUniversity Hospital, Toulouse·N/A·NCT04970472·1,000 enrolled
TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma
Recruiting·CCentre Francois Baclesse·Phase 2·NCT04678362·50 enrolled
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT05837806·21 enrolled
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT06405425·52 enrolled
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Recruiting·SSun Yat-sen University·Phase 2·NCT07241793·96 enrolled
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
Recruiting·Shanghai Hengrui Pharmaceutical Co., Ltd. logoShanghai Hengrui Pharmaceutical Co., Ltd.·Phase 3·NCT06738251·402 enrolled
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 2·NCT06823427·60 enrolled
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
Recruiting·NNagoya University·Phase 2·NCT06983210·43 enrolled
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Recruiting·FFlare Therapeutics Inc.·Phase 1·NCT05929235·120 enrolled
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
Recruiting·RRenJi Hospital·N/A·NCT05595408·84 enrolled
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06696742·60 enrolled
Probiotics in Advanced Urothelial Carcinoma
Recruiting·SSun Yat-sen University·Phase 2·NCT06904573·222 enrolled
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05868265·24 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)